Curis Lifescience’s IPO was subscribed 74.39 times on the last day. The retail quota was subscribed over 44.28 times, the NII was subscribed over 115.46 times, and the QIB was subscribed over 96.17 times.
Details About Curis Lifesciences IPO
Curis Lifesciences got approval from SEBI for an IPO of around ₹27.52 crores. Curis Lifesciences IPO consists of a fresh issue of ₹27.52 crores with a face value of ₹10 each.
Furthermore, Curis Lifesciences had a set price band of ₹120 to ₹128 per share.
In the Curis Lifesciences IPO, 2,000 shares were in 2 lot sizes for the retail minimum and maximum categories as well.
Moreover, 3,000 shares were in 3 lot sizes for the S-HNI Min category. 7,000 shares were in 7 lot sizes for the S-HNI Max category. And 8,000 shares were in 8 lot sizes for the B-HNI Min category.
To invest in the Curis Lifesciences IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum and maximum investment of ₹2,56,000.
- SHNI (S-HNI): Minimum investment of ₹3,84,000.
- SHNI (S-HNI): Maximum investment of ₹8,96,000
- BHNI Min: Minimum investment of ₹10,24,000
Curis Lifesciences IPO’s Subscription Duration
The opening date of Curis Lifesciences IPO was on November 7, 2025, and the closing date was on November 11, 2025. The allotment date of Curis Lifesciences’ IPO was on November 12, 2025, and the investors will receive a refund on November 13, 2025. Curis Lifesciences is set to be listed on November 14, 2025.
Curis Lifesciences IPO funds deployment
- The proceeds raised from the fresh issue will be utilized towards the Upgradation/Improvement of the existing Manufacturing Facilities.
- A portion of revenue towards the Construction of a Storage Facility
- Some funds will be used for the Pre-payment/Repayment of outstanding Secured Loans.
- A portion of it is used towards Product Registrations in other countries
- Lastly, the remaining funds will be used for the company’s general Corporate Purposes.
About Curis Lifesciences Company
Incorporated in 2010, Curis Lifesciences Limited is a prominent pharmaceutical company that manufactures a wide range of pharmaceutical products, including Tablets, Capsules, External Preparations, Oral liquids, and Sterile Ophthalmic Ointments. Curis Lifescience makes medicine in India and abroad under contract or license agreement, as well as for its own brand. Moreover, the company consists of a state-of-the-art factory in Sanand, Gujarat, through which they follow strict quality control checks to make sure each of their products is safe and works well. The company gets ready-made goods from manufacturers and distributes them to wholesalers and other clients nationwide. The company had a total of 95 permanent employees as of July 31, 2025. In addition to its two own-brand clients in Yemen and Kenya, the firm contracts with more than 100 corporate clients.
Curis Lifesciences IPO Company Financial Report
The company reported revenue of ₹49.65 crores in 2025 against ₹35.87 crores in 2024. The company reported a profit of ₹6.11 crores in 2025 against a profit of ₹4.87 crores in 2024.
